678 Updated safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): a phase Ib/II clinical trial

西妥昔单抗 医学 内科学 耐火材料(行星科学) 头颈部鳞状细胞癌 肿瘤科 临床终点 队列 无进展生存期 临床研究阶段 临床试验 头颈部癌 胃肠病学 放射治疗 化疗 癌症 物理 结直肠癌 天体生物学
作者
Ye Guo,Qiang Li,Desheng Hu,Song Qu,Youhua Zhu,Meiyu Fang,Wantao Chen,Chuan-Zheng Sun,Hao Jiang,Jingfeng Zong,Jinguan Lin,Siyang Wang,Wei Wang,Chuan Jin,Guochun Cao,Minghua Ge,Xiaoming Huang,Xudong Wang,Zhiming Li,Mo Wang,Xianming Luo,Shuang-Hui Wei,Yuteng Shen
标识
DOI:10.1136/jitc-2023-sitc2023.0678
摘要

Background

PD-1 inhibitors and EGFR inhibitors are effective and may provide potential synergy in R/M HNSCC. An open-label, multicenter phase Ib/II study of toripalimab (a humanized IgG4K monoclonal antibody specific for PD-1) with cetuximab was conducted in platinum-refractory or PD-L1 positive previously untreated R/M-HNSCC (NCT04856631). Here we report the results of Cohort A (platinum-refractory).

Methods

Eligible patients with R/M HNSCC progressed upon 1st-line platinum-containing treatment or developed R/M disease within 6 months of platinum-containing neo-adjuvant/adjuvant or chemo-radiation therapy who had no prior immunotherapy or EGFR inhibitors therapy were enrolled. Toripalimab was administered at 240mg intravenously (IV) Q3W and cetuximab was given as a loading dose of 400mg/m2 IV followed by 250mg/m2 QW. The primary endpoint was objective response rate (ORR) by an independent review committee (IRC) per RECIST v1.1. Secondary endpoints included ORR, disease control rates (DCR), duration of response (DOR), progression-free survival (PFS) by the investigators and IRC, overall survival (OS), and safety.

Results

By the data cutoff date of Apr. 14, 2023, a total of 45 patients including 35 (77.8%) males were enrolled in Cohort A, with the median follow-up duration of 10.0 months. The median age of the patients was 59 (range 32–74) years. Eighteen (40.0%) patients had distant metastases and 31 (68.9%) were PD-L1 CPS ≥1. As assessed by the IRC, the confirmed ORR was 60% (95% CI 44.3%, 74.3%) with 1 CR and 26 PR, and the median DOR was 17.9 (95% CI 7.8, NA) months, the median PFS was 9.9 (95% CI 4.2, NA) months, 12 months PFS rate was 40.7%. Similar results were seen per investigators' assessment. The median OS was 15.4 (95% CI 8.5, 17.7) months, 12 months OS rate was 54.4%. Patients with positive PD-L1 expression (CPS≥1) may benefit more than negative patients (ORR: 64.5% vs 40%, median PFS: 10.4 m vs 4.0 m, median OS: 15.4 m vs 11.7 m). Forty-two (93.3%) patients experienced treatment-related adverse events (TRAEs). Eleven (24.4%) patients experienced immune-related adverse events (irAEs). Ten (22.2%) patients occurred Grade≥3 TRAEs and no Grade≥3 irAEs occurred. No fatal AEs related to the study treatment was reported.

Conclusions

Toripalimab combined with cetuximab were well tolerated and showed promising clinical efficacy in patients with R/M HNSCC.

Trial Registration

NCT04856631

Ethics Approval

The study obtained ethics approval from Shanghai East Hospital Drug clinical Trial Ethics Committee [[2020]&x4E34;&x5BA1;&x7B2C; (072) &x53F7;], and participants gave informed consent before taking part.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天就是我完成签到,获得积分10
1秒前
1秒前
1秒前
KYRIELIU发布了新的文献求助10
1秒前
陈小小完成签到,获得积分10
2秒前
无聊的怀绿完成签到,获得积分10
2秒前
2秒前
冷静水蓝完成签到,获得积分10
2秒前
2秒前
qdsj2033完成签到,获得积分10
3秒前
Helic完成签到,获得积分10
4秒前
5秒前
冷静水蓝发布了新的文献求助10
5秒前
猪猪hero应助王乾龙采纳,获得10
5秒前
Leila完成签到,获得积分10
5秒前
橙子完成签到,获得积分10
5秒前
情怀应助walden采纳,获得10
5秒前
感动的老虎完成签到,获得积分10
6秒前
lizhiqian2024完成签到,获得积分10
6秒前
白石溪完成签到,获得积分10
6秒前
上官若男应助crystal01162采纳,获得10
6秒前
可爱的函函应助橘子海采纳,获得10
7秒前
Running完成签到 ,获得积分10
7秒前
肱二头肌完成签到,获得积分10
7秒前
8秒前
浩铭完成签到,获得积分10
8秒前
每天一篇文献的小王完成签到,获得积分10
8秒前
研友_Raven完成签到,获得积分10
9秒前
10秒前
关显锋发布了新的文献求助10
10秒前
逸兴遄飞完成签到,获得积分20
10秒前
没有花活儿完成签到,获得积分10
11秒前
高大代容发布了新的文献求助10
11秒前
12366666发布了新的文献求助20
11秒前
英吉利25发布了新的文献求助10
11秒前
自信的昊焱完成签到,获得积分10
11秒前
爱啃大虾发布了新的文献求助10
12秒前
大模型应助Tangyartie采纳,获得10
12秒前
云瑾完成签到,获得积分0
12秒前
Jasper应助冷静水蓝采纳,获得10
13秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 1000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976951
求助须知:如何正确求助?哪些是违规求助? 3521151
关于积分的说明 11206485
捐赠科研通 3257955
什么是DOI,文献DOI怎么找? 1798937
邀请新用户注册赠送积分活动 878029
科研通“疑难数据库(出版商)”最低求助积分说明 806723